HZNP Horizon Therapeutics Public Ltd Co

Price (delayed)

$78.72

Market cap

$17.37B

P/E Ratio

19.06

Dividend/share

N/A

EPS

$4.13

Enterprise value

$16.65B

Sector: Healthcare
Industry: Drug Manufacturers - General

Highlights

The equity has soared by 144% year-on-year and by 61% since the previous quarter
Horizon Therapeutics's quick ratio has surged by 141% QoQ and by 54% YoY
The stock's price to earnings (P/E) is 29% more than its last 4 quarters average of 14.8

Key stats

What are the main financial stats of HZNP
Market
Shares outstanding
220.71M
Market cap
$17.37B
Enterprise value
$16.65B
Valuations
Price to earnings (P/E)
19.06
Price to book (P/B)
4.28
Price to sales (P/S)
9.19
EV/EBIT
60.72
EV/EBITDA
30.61
EV/Sales
9.15
Earnings
Revenue
$1.82B
EBIT
$274.18M
EBITDA
$543.91M
Free cash flow
$197.32M
Per share
EPS
$4.13
Free cash flow per share
$0.93
Book value per share
$18.39
Revenue per share
$8.57
TBVPS
$16.51
Balance sheet
Total assets
$5.77B
Total liabilities
$1.97B
Debt
$1B
Equity
$3.8B
Working capital
$1.95B
Liquidity
Debt to equity
0.26
Current ratio
3.49
Quick ratio
3.11
Net debt/EBITDA
-1.34
Margins
EBITDA margin
29.9%
Gross margin
74.4%
Net margin
43.5%
Operating margin
16.8%
Efficiency
Return on assets
16.6%
Return on equity
30.1%
Return on invested capital
14.2%
Return on capital employed
5.5%
Return on sales
15.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HZNP stock price

How has the Horizon Therapeutics stock price performed over time
Intraday
-0.24%
1 week
-1.03%
1 month
2.1%
1 year
108.59%
YTD
7.61%
QTD
7.61%

Financial performance

How have Horizon Therapeutics's revenue and profit performed over time
Revenue
$1.82B
Gross profit
$1.35B
Operating income
$305.67M
Net income
$792.01M
Gross margin
74.4%
Net margin
43.5%
The operating income has surged by 143% since the previous quarter and by 98% year-on-year
The company's operating margin has surged by 102% QoQ and by 41% YoY
HZNP's net income has surged by 53% since the previous quarter
HZNP's gross profit is up by 46% year-on-year and by 21% since the previous quarter

Growth

What is Horizon Therapeutics's growth rate over time

Valuation

What is Horizon Therapeutics stock price valuation
P/E
19.06
P/B
4.28
P/S
9.19
EV/EBIT
60.72
EV/EBITDA
30.61
EV/Sales
9.15
Horizon Therapeutics's EPS has increased by 45% from the previous quarter
The stock's price to earnings (P/E) is 29% more than its last 4 quarters average of 14.8
The equity has soared by 144% year-on-year and by 61% since the previous quarter
HZNP's price to book (P/B) is 53% higher than its 5-year quarterly average of 2.8 and 19% higher than its last 4 quarters average of 3.6
HZNP's price to sales (P/S) is 163% more than its 5-year quarterly average of 3.5 and 46% more than its last 4 quarters average of 6.3
Horizon Therapeutics's revenue has increased by 41% YoY and by 20% from the previous quarter

Efficiency

How efficient is Horizon Therapeutics business performance
HZNP's return on invested capital has surged by 118% year-on-year
Horizon Therapeutics's ROS has soared by 104% YoY
Horizon Therapeutics's return on assets has increased by 36% QoQ
HZNP's ROE is up by 20% from the previous quarter

Dividends

What is HZNP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HZNP.

Financial health

How did Horizon Therapeutics financials performed over time
The total assets is 193% more than the total liabilities
Horizon Therapeutics's quick ratio has surged by 141% QoQ and by 54% YoY
Horizon Therapeutics's current ratio has surged by 131% QoQ and by 50% YoY
The company's debt is 74% lower than its equity
The equity has soared by 144% year-on-year and by 61% since the previous quarter
The debt to equity has dropped by 70% year-on-year and by 48% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.